Hanmi Pharmaceutical announced that they signed an export contract of injectable arthritis drug 'Hyalrheuma' with U.S. company Actavis

On July 21, Hanmi Pharmaceutical announced that they signed an export contract of injectable arthritis drug 'Hyalrheuma' with the no.1 U.S. generic pharmaceutical company Actavis (President Paul Bisaro).

Through the contract, Actavis which records annual sales of about 10 trillion won, will sell Hyalrheuma exclusively in U.S. for 12 years, and Hanmi is expected to achieve sales of more than $ ...